Mattias Aronsson1, Josefine Persson2, Christian Blomstrand2, Per Wester2, Lars-Åke Levin2. 1. From the Department of Medical and Health Sciences (M.A., L.-Å.L.), Linkoping University; Department of Clinical Neuroscience and Rehabilitation at the Sahlgrenska Academy (J.P., C.B.), University of Gothenburg; Department of Public Health and Clinical Science (P.W.), University of Umea; and Department of Clinical Sciences (P.W.), Danderyd Hospital, Karolinska Institutet, Sweden. mattias.aronsson@liu.se. 2. From the Department of Medical and Health Sciences (M.A., L.-Å.L.), Linkoping University; Department of Clinical Neuroscience and Rehabilitation at the Sahlgrenska Academy (J.P., C.B.), University of Gothenburg; Department of Public Health and Clinical Science (P.W.), University of Umea; and Department of Clinical Sciences (P.W.), Danderyd Hospital, Karolinska Institutet, Sweden.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of adding endovascular thrombectomy to standard care in patients with acute ischemic stroke. METHODS: The cost-effectiveness analysis of endovascular thrombectomy in patients with acute ischemic stroke was based on a decision-analytic Markov model. Primary outcomes from ESCAPE, Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA), Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT), and Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) along with data from published studies and registries were used in this analysis. We used a health care payer perspective and a lifelong time horizon to estimate costs and effects. RESULTS: The model showed that adding thrombectomy with stent retrievers to guideline-based care (including IV thrombolysis) resulted in a gain of 0.40 life-years and 0.99 quality-adjusted life-years along with a cost savings of approximately $221 per patient. The sensitivity analysis showed that the results were not sensitive to changes in uncertain parameters or assumptions. CONCLUSIONS: Adding endovascular treatment to standard care resulted in substantial clinical benefits at low costs. The results were consistent throughout irrespective of whether data from ESCAPE, EXTEND-IA, MR CLEAN, REVASCAT, or SWIFT PRIME were used in this model.
RCT Entities:
OBJECTIVE: To evaluate the cost-effectiveness of adding endovascular thrombectomy to standard care in patients with acute ischemic stroke. METHODS: The cost-effectiveness analysis of endovascular thrombectomy in patients with acute ischemic stroke was based on a decision-analytic Markov model. Primary outcomes from ESCAPE, Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA), Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT), and Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) along with data from published studies and registries were used in this analysis. We used a health care payer perspective and a lifelong time horizon to estimate costs and effects. RESULTS: The model showed that adding thrombectomy with stent retrievers to guideline-based care (including IV thrombolysis) resulted in a gain of 0.40 life-years and 0.99 quality-adjusted life-years along with a cost savings of approximately $221 per patient. The sensitivity analysis showed that the results were not sensitive to changes in uncertain parameters or assumptions. CONCLUSIONS: Adding endovascular treatment to standard care resulted in substantial clinical benefits at low costs. The results were consistent throughout irrespective of whether data from ESCAPE, EXTEND-IA, MR CLEAN, REVASCAT, or SWIFT PRIME were used in this model.
Authors: Mayank Goyal; Mohammed A Almekhlafi; Christoph Cognard; Ryan McTaggart; Kristine Blackham; Alessandra Biondi; Aad van der Lugt; Charles B L M Majoie; Wim H van Zwam; H Bart van der Worp; Michael D Hill Journal: Neuroradiology Date: 2019-01 Impact factor: 2.804
Authors: Silke Walter; Iris Q Grunwald; Stefan A Helwig; Andreas Ragoschke-Schumm; Michael Kettner; Mathias Fousse; Martin Lesmeister; Klaus Fassbender Journal: Curr Atheroscler Rep Date: 2018-08-29 Impact factor: 5.113
Authors: Fernando de Andrés-Nogales; María Álvarez; María Ángeles de Miquel; Tomás Segura; Alberto Gil; Pere Cardona; Miguel Ángel Casado; Raul G Nogueira; Antoni Dávalos Journal: Eur Stroke J Date: 2017-08-01
Authors: Nuno Martins; Ana Aires; Beatriz Mendez; Sandra Boned; Marta Rubiera; Alejandro Tomasello; Pilar Coscojuela; David Hernandez; Marián Muchada; David Rodríguez-Luna; Noelia Rodríguez; Jesús M Juega; Jorge Pagola; Carlos A Molina; Marc Ribó Journal: Interv Neurol Date: 2018-08-31
Authors: Kit N Simpson; Annie N Simpson; Patrick D Mauldin; Yuko Y Palesch; Sharon D Yeatts; Dawn Kleindorfer; Thomas A Tomsick; Lydia D Foster; Andrew M Demchuk; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Rüdiger von Kummer; Carlos A Molina; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Joseph P Broderick Journal: J Am Heart Assoc Date: 2017-05-08 Impact factor: 5.501
Authors: Bruce C V Campbell; Peter J Mitchell; Leonid Churilov; Mahsa Keshtkaran; Keun-Sik Hong; Timothy J Kleinig; Helen M Dewey; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Atte Meretoja; Dominique A Cadilhac; Geoffrey A Donnan; Stephen M Davis Journal: Front Neurol Date: 2017-12-14 Impact factor: 4.003